Literature DB >> 2501456

Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.

P A Kempster1, J P Frankel, M Bovingdon, R Webster, A J Lees, G M Stern.   

Abstract

To assess the relative influence of central pharmacodynamic and peripheral pharmacokinetic factors on the duration of motor response to levodopa, the relationship between motor function and plasma levodopa levels was studied in 31 Parkinsonian patients. Duration of benefit from single levodopa doses while fasting depended on the degree to which the plasma levodopa level had declined over four hours; wearing off occurred when the plasma levodopa level had fallen to approximately 50% of peak concentration, irrespective of the duration of the motor response. Whilst the amplitude of motor response to levodopa is likely to be modified by alternations in dopamine receptor stimulation and sensitivity as the disease progresses, it is proposed that the duration of response is primarily determined by levodopa peripheral pharmacokinetics rather than by central pharmacodynamic factors associated with dopamine storage capacity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2501456      PMCID: PMC1032021          DOI: 10.1136/jnnp.52.6.718

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

1.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

2.  Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations.

Authors:  S T Gancher; J G Nutt; W Woodward
Journal:  Neurology       Date:  1988-05       Impact factor: 9.910

3.  Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients.

Authors:  S T Gancher; J G Nutt; W R Woodward
Journal:  Neurology       Date:  1987-06       Impact factor: 9.910

4.  "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.

Authors:  S Fahn
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

5.  Critical analysis of the disability in Parkinson's disease.

Authors:  D D Webster
Journal:  Mod Treat       Date:  1968-03

6.  On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.

Authors:  I Shoulson; G A Glaubiger; T N Chase
Journal:  Neurology       Date:  1975-12       Impact factor: 9.910

7.  Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.

Authors:  P A Kempster; W R Gibb; G M Stern; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

8.  Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism.

Authors:  E Melamed; F Hefti; D J Pettibone; J Liebman; R J Wurtman
Journal:  Neurology       Date:  1981-06       Impact factor: 9.910

9.  Success and problems of long-term levodopa therapy in Parkinson's disease.

Authors:  C D Marsden; J D Parkes
Journal:  Lancet       Date:  1977-02-12       Impact factor: 79.321

  9 in total
  24 in total

1.  The dopaminergic response in multiple system atrophy.

Authors:  A J Hughes; C Colosimo; B Kleedorfer; S E Daniel; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

2.  Ropinirole (SK and F 101468) in the treatment of Parkinson's disease.

Authors:  B Kleedorfer; G M Stern; A J Lees; J M Bottomley; N Sree-Haran
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-10       Impact factor: 10.154

3.  Intranasal apomorphine: a new treatment in Parkinson's disease.

Authors:  R Kapoor; N Turjanski; J Frankel; B Kleedorfer; A Lees; G Stern; M Bovingdon; R Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

4.  Diurnal differences in response to oral levodopa.

Authors:  J P Frankel; Z Pirtosek; P A Kempster; M Bovingdon; R Webster; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

5.  Comparison of motor response to apomorphine and levodopa in Parkinson's disease.

Authors:  P A Kempster; J P Frankel; G M Stern; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

6.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.

Authors:  C Colosimo; M Merello; A J Hughes; K Sieradzan; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

7.  Sublingual apomorphine and Parkinson's disease.

Authors:  A J Lees; J L Montastruc; N Turjanski; O Rascol; B Kleedorfer; H Peyro Saint-Paul; G M Stern; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

8.  Marijuana for parkinsonian tremor.

Authors:  J P Frankel; A Hughes; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-05       Impact factor: 10.154

9.  Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation.

Authors:  S Harder; H Baas; N Bergemann; L Demisch; S Rietbrock
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

10.  Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years.

Authors:  A J Hughes; J P Frankel; P A Kempster; G M Stern; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.